Trisk Bio

Executive Summary

Trisk Bio is a UK-based biotechnology company founded in 2021 that specializes in scalable preclinical adeno-associated virus (AAV) manufacturing services. The company provides research-grade and non-human primate (NHP) study-grade AAV vectors to gene therapy developers, enabling affordable and efficient preclinical studies for rare diseases and genetic disorders. By focusing on process development and scalable production, Trisk Bio addresses a critical bottleneck in gene therapy development: access to high-quality, cost-effective AAV vectors for early-stage research. Founded in London, the company operates in the rapidly growing gene therapy and rare disease sectors, positioning itself as a key service provider to biotech and pharmaceutical clients. Trisk Bio’s value proposition lies in its specialization in preclinical AAV manufacturing, a segment with high demand as gene therapies advance toward clinical trials. The company's services support the transition from discovery to IND-enabling studies, potentially accelerating timelines for developers. With no disclosed funding rounds or valuation, Trisk Bio remains an early-stage private entity. Its success hinges on securing partnerships with gene therapy developers and expanding its manufacturing capacity to meet growing demand. The company operates in a competitive landscape but benefits from the trend toward outsourcing non-core manufacturing activities. Future growth will depend on its ability to demonstrate reliability, scalability, and cost advantages over in-house production or larger contract manufacturing organizations.

Upcoming Catalysts (preview)

• H2 2026Announcement of a strategic partnership with a gene therapy developer60% success
• 2026Series A financing round to expand manufacturing capacity70% success
• Q3 2026Publication of a case study demonstrating successful NHP study vector supply50% success